Treatment of Heparin-induced Thrombocytopenia in Subacute HIT A

Anticoagulant selection in subacute HIT A requires specific guidance — the choice of agent in this setting is informed by evidence-based recommendations that differ from general anticoagulation practice.

Clinical Scenario

This protocol applies to patients with subacute HIT A — a distinct presentation within the spectrum of heparin-induced thrombocytopenia that carries its own evidence-based anticoagulation recommendations.

Treatment Approach

Current guidelines recommend a direct oral anticoagulant (DOAC) over an alternative class of anticoagulant in this setting. The specific agent selection and supporting clinical considerations are covered in the full protocol.

Full regimen details, agent-level guidance, and clinical decision points available via the link below.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1182/bloodadvances.2018024489

In patients with subacute HIT A, the ASH guideline panel suggests treatment with a DOAC (eg, dabigatran, rivaroxaban, or apixaban) rather than a VKA (conditional recommendation, moderate certainty in the evidence about effects).

View source ↗